Literature DB >> 24684389

Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Amos A Fatokun1, Valina L Dawson, Ted M Dawson.   

Abstract

Cells die by a variety of mechanisms. Terminally differentiated cells such as neurones die in a variety of disorders, in part, via parthanatos, a process dependent on the activity of poly (ADP-ribose)-polymerase (PARP). Parthanatos does not require the mediation of caspases for its execution, but is clearly mechanistically dependent on the nuclear translocation of the mitochondrial-associated apoptosis-inducing factor (AIF). The nuclear translocation of this otherwise beneficial mitochondrial protein, occasioned by poly (ADP-ribose) (PAR) produced through PARP overactivation, causes large-scale DNA fragmentation and chromatin condensation, leading to cell death. This review describes the multistep course of parthanatos and its dependence on PAR signalling and nuclear AIF translocation. The review also discusses potential targets in the parthanatos cascade as promising avenues for the development of novel, disease-modifying, therapeutic agents.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  AIF; PARP-1; cell death; mitochondria; parthanatos; therapy

Mesh:

Substances:

Year:  2014        PMID: 24684389      PMCID: PMC3976618          DOI: 10.1111/bph.12416

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  181 in total

1.  Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster.

Authors:  Shuji Hanai; Masayuki Kanai; Sayaka Ohashi; Keiji Okamoto; Mitsunori Yamada; Hitoshi Takahashi; Masanao Miwa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

2.  Poly(ADP-ribose) (PAR) polymer is a death signal.

Authors:  Shaida A Andrabi; No Soo Kim; Seong-Woon Yu; Hongmin Wang; David W Koh; Masayuki Sasaki; Judith A Klaus; Takashi Otsuka; Zhizheng Zhang; Raymond C Koehler; Patricia D Hurn; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Activation of cell death mediated by apoptosis-inducing factor due to the absence of poly(ADP-ribose) glycohydrolase.

Authors:  Yiran Zhou; Xiaoxing Feng; David W Koh
Journal:  Biochemistry       Date:  2011-03-21       Impact factor: 3.162

4.  Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia.

Authors:  F Moroni; E Meli; F Peruginelli; A Chiarugi; A Cozzi; R Picca; P Romagnoli; R Pellicciari; D E Pellegrini-Giampietro
Journal:  Cell Death Differ       Date:  2001-09       Impact factor: 15.828

5.  Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion.

Authors:  Aaron M Hamby; Sang Won Suh; Tiina M Kauppinen; Raymond A Swanson
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

6.  Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia.

Authors:  Carsten Culmsee; Changlian Zhu; Stefan Landshamer; Barbara Becattini; Ernst Wagner; Maurizio Pellecchia; Maurizio Pellechia; Klas Blomgren; Nikolaus Plesnila
Journal:  J Neurosci       Date:  2005-11-02       Impact factor: 6.167

7.  Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats.

Authors:  K Takahashi; J H Greenberg; P Jackson; K Maclin; J Zhang
Journal:  J Cereb Blood Flow Metab       Date:  1997-11       Impact factor: 6.200

8.  The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease.

Authors:  Judit Soós; József I Engelhardt; László Siklós; László Havas; Katalin Majtényi
Journal:  Neuroreport       Date:  2004-08-06       Impact factor: 1.837

9.  Astrocytic poly(ADP-ribose) polymerase-1 activation leads to bioenergetic depletion and inhibition of glutamate uptake capacity.

Authors:  Kim San Tang; Sang Won Suh; Conrad C Alano; Zongjun Shao; Waylon T Hunt; Raymond A Swanson; Christopher M Anderson
Journal:  Glia       Date:  2010-03       Impact factor: 7.452

Review 10.  Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos.

Authors:  Yingfei Wang; Valina L Dawson; Ted M Dawson
Journal:  Exp Neurol       Date:  2009-03-28       Impact factor: 5.330

View more
  173 in total

1.  Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death.

Authors:  Anna A Kondratova; HyeonJoo Cheon; Beihua Dong; Elise G Holvey-Bates; Metis Hasipek; Irina Taran; Christina Gaughan; Babal K Jha; Robert H Silverman; George R Stark
Journal:  EMBO J       Date:  2020-04-23       Impact factor: 11.598

2.  Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia.

Authors:  Fei Teng; Ling Zhu; Junhui Su; Xi Zhang; Ning Li; Zhiyu Nie; Lingjing Jin
Journal:  Neurochem Res       Date:  2016-02-11       Impact factor: 3.996

3.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

Review 4.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

5.  Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis.

Authors:  Shaida A Andrabi; George K E Umanah; Calvin Chang; Daniel A Stevens; Senthilkumar S Karuppagounder; Jean-Philippe Gagné; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-01       Impact factor: 11.205

6.  Activation of the Akt1-CREB pathway promotes RNF146 expression to inhibit PARP1-mediated neuronal death.

Authors:  Hyojung Kim; Jisoo Park; Hojin Kang; Seung Pil Yun; Yun-Song Lee; Yun-Il Lee; Yunjong Lee
Journal:  Sci Signal       Date:  2020-12-22       Impact factor: 8.192

Review 7.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 8.  DNA Damage, DNA Repair, Aging, and Neurodegeneration.

Authors:  Scott Maynard; Evandro Fei Fang; Morten Scheibye-Knudsen; Deborah L Croteau; Vilhelm A Bohr
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-18       Impact factor: 6.915

9.  FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.

Authors:  Changsun Yu; Bok-Seok Kim; Eunhee Kim
Journal:  Cell Death Differ       Date:  2016-09-23       Impact factor: 15.828

10.  Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.

Authors:  Lisa Rank; Sebastian Veith; Eva C Gwosch; Janine Demgenski; Magdalena Ganz; Marjolijn C Jongmans; Christopher Vogel; Arthur Fischbach; Stefanie Buerger; Jan M F Fischer; Tabea Zubel; Anna Stier; Christina Renner; Michael Schmalz; Sascha Beneke; Marcus Groettrup; Roland P Kuiper; Alexander Bürkle; Elisa Ferrando-May; Aswin Mangerich
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.